X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used in the clinical development of PIPE-307, a small molecule G1 receptor inhibitor. it is being evaluated in the Phase II clinical trial studies for the treatment of Relapsing-remitting Multiple Sclerosis.
Lead Product(s): PIPE-307
Therapeutic Area: Neurology Product Name: PIPE-307
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 04, 2024
Details:
The net proceeds will be used in the clinical development of PIPE-307, a small molecule G1 receptor inhibitor. it is being evaluated in the Phase II clinical trial studies for the treatment of Relapsing-remitting Multiple Sclerosis.
Lead Product(s): PIPE-307
Therapeutic Area: Neurology Product Name: PIPE-307
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jeffrey C. Thacker
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering March 15, 2024
Details:
PIPE-791 is a potent, selective and brain-penetrant small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1), which is investigated for the treatment of MS and other neurological and systemic diseases.
Lead Product(s): PIPE-791
Therapeutic Area: Neurology Product Name: PIPE-791
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
PIPE-791 is a potent, selective, brain-penetrant small molecule antagonist of the LPA1 receptor that has demonstrated activity in in vitro and in vivo models and was tolerated in IND-enabling studies for Multiple sclerosis.
Lead Product(s): PIPE-791
Therapeutic Area: Neurology Product Name: PIPE-791
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
The agreement leverages Pipeline’s expertise in precision neuroregeneration and Janssen’s development experience across nervous system disorders for the investigational compound, PIPE-307, an oral, highly selective antagonist of the muscarinic M1 receptor.
Lead Product(s): PIPE-307
Therapeutic Area: Neurology Product Name: PIPE-307
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $1,100.0 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement April 17, 2023
Details:
PIPE-791 is a preclinical program and focuses on antagonism of the LPA1 receptor. LPA is a naturally occurring inflammatory lipid and its dysregulation has been implicated in inflammatory diseases, such as MS.
Lead Product(s): PIPE-791
Therapeutic Area: Neurology Product Name: PIPE-791
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
PIPE 791, a lysophosphatidic acid (LPA1) receptor antagonist is being developed by Pipeline Therapeutics for the treatment of demyelinating disorders.
Lead Product(s): PIPE-791
Therapeutic Area: Neurology Product Name: PIPE-791
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
PIPE-307, highly selective antagonist of M1 muscarinic receptor commencing clinical studies in MS patients. Results from PET study demonstrate that doses tested in Phase 1 study achieve a level of uptake in human brain.
Lead Product(s): PIPE-307
Therapeutic Area: Neurology Product Name: PIPE-307
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
PIPE-307, as a first-in-class myelin restoration therapeutic, demonstrated linear pharmacokinetic (PK) data consistent with preclinical modeling and was generally well tolerated across all dose cohorts.
Lead Product(s): PIPE-307
Therapeutic Area: Neurology Product Name: PIPE-307
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
The randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of PIPE-307 will primarily assess the safety and tolerability profile of PIPE-307, as well as measure the effect of PIPE-307 on pharmacokinetics.
Lead Product(s): PIPE-307
Therapeutic Area: Immunology Product Name: PIPE-307
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
